The stock of Concordia International Corp (NASDAQ:CXRX) hit a new 52-week low and has $3.05 target or 12.00% below today’s $3.47 share price. The 5 months bearish chart indicates high risk for the $187.23 million company. The 1-year low was reported on Oct, 17 by Barchart.com. If the $3.05 price target is reached, the company will be worth $22.47 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 539,678 shares traded hands. Concordia International Corp (NASDAQ:CXRX) has declined 89.17% since March 14, 2016 and is downtrending. It has underperformed by 94.79% the S&P500.
Analysts await Concordia International Corp (NASDAQ:CXRX) to report earnings on November, 10. They expect $1.35 earnings per share, up 3.05% or $0.04 from last year’s $1.31 per share. CXRX’s profit will be $72.84M for 0.64 P/E if the $1.35 EPS becomes a reality. After $1.21 actual earnings per share reported by Concordia International Corp for the previous quarter, Wall Street now forecasts 11.57% EPS growth.
Concordia International Corp (NASDAQ:CXRX) Ratings Coverage
Out of 9 analysts covering Concordia Healthcare Corp. (NASDAQ:CXRX), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. Concordia Healthcare Corp. has been the topic of 18 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Laurentian on Tuesday, March 29. Scotia Capital maintained the stock with “Sector Outperform” rating in Tuesday, September 29 report. The firm has “Buy” rating given on Tuesday, August 11 by Canaccord Genuity. IBC initiated Concordia International Corp (NASDAQ:CXRX) on Monday, November 30 with “Sector Perform” rating. The firm earned “Sector Outperform” rating on Friday, October 16 by Scotia Capital. The firm earned “Buy” rating on Friday, October 16 by S&P Research. GMP Securities downgraded the stock to “Hold” rating in Monday, August 15 report. The firm earned “Hold” rating on Thursday, August 4 by TD Securities. The firm has “Neutral” rating given on Monday, August 15 by Goldman Sachs. Goldman Sachs initiated it with “Neutral” rating and $32 target price in Monday, June 6 report.
According to Zacks Investment Research, “Concordia International Corp is a diverse pharmaceutical company which focused on legacy pharmaceutical products and orphan drugs. The company also markets orphan drugs through its Orphan Drug Division, currently consisting of Photofrin(R) for the treatment of certain rare forms of cancer, which is currently undergoing testing for potential new indications. Concordia International Corp, formerly known as Concordia Healthcare Corp, is headquartered in Oakville, Canada.”
More important recent Concordia International Corp (NASDAQ:CXRX) news were published by: Business.Financialpost.com which released: “Concordia International Corp. faces much more downside â€“ CIBC” on October 14, 2016, also Business.Financialpost.com published article titled: “Concordia International Corp takeover unlikely â€“ Goldman”, Fool.ca published: “Concordia International Corp.: A Safe Buy?” on October 10, 2016. More interesting news about Concordia International Corp (NASDAQ:CXRX) was released by: Globenewswire.com and their article: “DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Concordia …” with publication date: September 29, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.